Non-small Cell Lung Cancer Drugs Market, Global Outlook and Forecast 2022-2028

March 2022 | 62 pages | ID: N9681499D6D2EN
Market Monitor Global

Abstracts

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.

This report contains market size and forecasts of Non-small Cell Lung Cancer Drugs in Global, including the following market information:

Global Non-small Cell Lung Cancer Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Non-small Cell Lung Cancer Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Biologics Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Non-small Cell Lung Cancer Drugs include AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd and Merck & Co., Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-small Cell Lung Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Non-small Cell Lung Cancer Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Type, 2021 (%)

• Biologics
• Small Molecule Targeted Therapy
• Chemotherapy
• Other

Global Non-small Cell Lung Cancer Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Application, 2021 (%)

• Lung Adenocarcinoma
• Squamous Cell Lung Carcinoma
• Large-cell Lung Carcinoma

Global Non-small Cell Lung Cancer Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Non-small Cell Lung Cancer Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Non-small Cell Lung Cancer Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AstraZeneca
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Non-small Cell Lung Cancer Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Non-small Cell Lung Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NON-SMALL CELL LUNG CANCER DRUGS OVERALL MARKET SIZE

2.1 Global Non-small Cell Lung Cancer Drugs Market Size: 2021 VS 2028
2.2 Global Non-small Cell Lung Cancer Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Non-small Cell Lung Cancer Drugs Players in Global Market
3.2 Top Global Non-small Cell Lung Cancer Drugs Companies Ranked by Revenue
3.3 Global Non-small Cell Lung Cancer Drugs Revenue by Companies
3.4 Top 3 and Top 5 Non-small Cell Lung Cancer Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-small Cell Lung Cancer Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-small Cell Lung Cancer Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Non-small Cell Lung Cancer Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Non-small Cell Lung Cancer Drugs Market Size Markets, 2021 & 2028
  4.1.2 Biologics
  4.1.3 Small Molecule Targeted Therapy
  4.1.4 Chemotherapy
  4.1.5 Other
4.2 By Type - Global Non-small Cell Lung Cancer Drugs Revenue & Forecasts
  4.2.1 By Type - Global Non-small Cell Lung Cancer Drugs Revenue, 2017-2022
  4.2.2 By Type - Global Non-small Cell Lung Cancer Drugs Revenue, 2023-2028
  4.2.3 By Type - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Non-small Cell Lung Cancer Drugs Market Size, 2021 & 2028
  5.1.2 Lung Adenocarcinoma
  5.1.3 Squamous Cell Lung Carcinoma
  5.1.4 Large-cell Lung Carcinoma
5.2 By Application - Global Non-small Cell Lung Cancer Drugs Revenue & Forecasts
  5.2.1 By Application - Global Non-small Cell Lung Cancer Drugs Revenue, 2017-2022
  5.2.2 By Application - Global Non-small Cell Lung Cancer Drugs Revenue, 2023-2028
  5.2.3 By Application - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Non-small Cell Lung Cancer Drugs Market Size, 2021 & 2028
6.2 By Region - Global Non-small Cell Lung Cancer Drugs Revenue & Forecasts
  6.2.1 By Region - Global Non-small Cell Lung Cancer Drugs Revenue, 2017-2022
  6.2.2 By Region - Global Non-small Cell Lung Cancer Drugs Revenue, 2023-2028
  6.2.3 By Region - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Non-small Cell Lung Cancer Drugs Revenue, 2017-2028
  6.3.2 US Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.3.3 Canada Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.3.4 Mexico Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Non-small Cell Lung Cancer Drugs Revenue, 2017-2028
  6.4.2 Germany Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.4.3 France Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.4.4 U.K. Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.4.5 Italy Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.4.6 Russia Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.4.7 Nordic Countries Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.4.8 Benelux Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Non-small Cell Lung Cancer Drugs Revenue, 2017-2028
  6.5.2 China Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.5.3 Japan Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.5.4 South Korea Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.5.5 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.5.6 India Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Non-small Cell Lung Cancer Drugs Revenue, 2017-2028
  6.6.2 Brazil Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.6.3 Argentina Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue, 2017-2028
  6.7.2 Turkey Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.7.3 Israel Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.7.4 Saudi Arabia Non-small Cell Lung Cancer Drugs Market Size, 2017-2028
  6.7.5 UAE Non-small Cell Lung Cancer Drugs Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AstraZeneca
  7.1.1 AstraZeneca Corporate Summary
  7.1.2 AstraZeneca Business Overview
  7.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Major Product Offerings
  7.1.4 AstraZeneca Non-small Cell Lung Cancer Drugs Revenue in Global Market (2017-2022)
  7.1.5 AstraZeneca Key News
7.2 Bristol-Myers Squibb Company
  7.2.1 Bristol-Myers Squibb Company Corporate Summary
  7.2.2 Bristol-Myers Squibb Company Business Overview
  7.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Major Product Offerings
  7.2.4 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue in Global Market (2017-2022)
  7.2.5 Bristol-Myers Squibb Company Key News
7.3 Eli Lilly and Company
  7.3.1 Eli Lilly and Company Corporate Summary
  7.3.2 Eli Lilly and Company Business Overview
  7.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Major Product Offerings
  7.3.4 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue in Global Market (2017-2022)
  7.3.5 Eli Lilly and Company Key News
7.4 F. Hoffmann-La Roche Ltd
  7.4.1 F. Hoffmann-La Roche Ltd Corporate Summary
  7.4.2 F. Hoffmann-La Roche Ltd Business Overview
  7.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Major Product Offerings
  7.4.4 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue in Global Market (2017-2022)
  7.4.5 F. Hoffmann-La Roche Ltd Key News
7.5 Merck & Co., Inc.
  7.5.1 Merck & Co., Inc. Corporate Summary
  7.5.2 Merck & Co., Inc. Business Overview
  7.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Major Product Offerings
  7.5.4 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue in Global Market (2017-2022)
  7.5.5 Merck & Co., Inc. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Non-small Cell Lung Cancer Drugs Market Opportunities & Trends in Global Market
Table 2. Non-small Cell Lung Cancer Drugs Market Drivers in Global Market
Table 3. Non-small Cell Lung Cancer Drugs Market Restraints in Global Market
Table 4. Key Players of Non-small Cell Lung Cancer Drugs in Global Market
Table 5. Top Non-small Cell Lung Cancer Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-small Cell Lung Cancer Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-small Cell Lung Cancer Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-small Cell Lung Cancer Drugs Product Type
Table 9. List of Global Tier 1 Non-small Cell Lung Cancer Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca Non-small Cell Lung Cancer Drugs Product Offerings
Table 32. AstraZeneca Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Company Corporate Summary
Table 34. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Offerings
Table 35. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Eli Lilly and Company Corporate Summary
Table 37. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Offerings
Table 38. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), (2017-2022)
Table 39. F. Hoffmann-La Roche Ltd Corporate Summary
Table 40. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Offerings
Table 41. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Merck & Co., Inc. Corporate Summary
Table 43. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product Offerings
Table 44. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Non-small Cell Lung Cancer Drugs Segment by Type in 2021
Figure 2. Non-small Cell Lung Cancer Drugs Segment by Application in 2021
Figure 3. Global Non-small Cell Lung Cancer Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-small Cell Lung Cancer Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-small Cell Lung Cancer Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-small Cell Lung Cancer Drugs Revenue in 2021
Figure 8. By Type - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 12. US Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 24. China Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)